Childhood Infratentorial Ependymoma Clinical Trial
Official title:
Examination of the Multiple Genetic and Molecular Targets as Therapeutic Options for Patients With Ependymoma Treated by the Phase II Children's Oncology Group Study ACNS0121
This research trial studies tumor samples from patients with ependymoma treated on the Children Oncology Group ACNS0121 trial. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PRIMARY OBJECTIVES:
I. To examine the prognostic role of histopathological variables, in particular cellular
density, mitotic count, and tumor cell invasion in intracranial pediatric ependymomas.
II. To study whether hTERT expression and telomere dysfunction correlate with
progression-free survival (PFS) and overall survival (OS) in pediatric intracranial
ependymoma.
III. To perform a genome-wide copy number screen and validation of copy number abnormalities
(CNAs) on formalin-fixed paraffin-embedded (FFPE) ependymomas using Affymetrix Molecular
Inversion Probe (MIP) arrays and interphase fluorescence in situ hybridization (iFISH). IV.
To evaluate associations between infiltration of immune markers and PFS as well as OS in
pediatric ependymoma.
V. To examine the role of 1q gain and 9p deletion in pediatric ependymomas by exploring
their association with PFS and OS in a multivariable model.
VI. To establish the frequency and clinicopathological associations of mutations in genes
involved in Notch pathway signaling.
OUTLINE:
Archived tumor tissue samples are analyzed for cellular density, mitotic count, tumor cell
invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic
mutations by IHC, Affymetrix Molecular Inversion Probe (MIP) arrays, and fluorescence in
situ hybridization (FISH). Results are then correlated with patient-outcome variables and
known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs.
supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well
as pathologic variables.
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00052780 -
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
|
Phase 1 | |
Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00100880 -
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
|
Phase 1 | |
Terminated |
NCT01088763 -
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Completed |
NCT00326664 -
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
|
Phase 1 | |
Completed |
NCT00363272 -
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00946335 -
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
|
Phase 1 | |
Completed |
NCT00063973 -
Cilengitide in Treating Children With Refractory Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT01462695 -
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
|
Phase 2 | |
Completed |
NCT01076530 -
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
|
Phase 1 | |
Completed |
NCT00919750 -
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
|